You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 2, February 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis?

A. Ayala, J. M. Kisala, J. A. Felt, M. M. Perrin and I. H. Chaudry
Department of Surgery, Michigan State University, East Lansing 48824.

Mice were subjected to sepsis by cecal ligation and puncture to determine whether macrophages from endotoxin-tolerant C3H/HeJ mice are also activated systemically to release inflammatory monokines associated with septic mortality. Blood levels of both tumor necrosis factor and interleukin 6 were significantly elevated during the first 1 to 4 hours of sepsis as compared with sham controls. Peritoneal macrophages from septic mice exhibited a marked spontaneous release of interleukin 1, interleukin 6, and tumor necrosis factor at 1 hour. However, the addition of endotoxin to macrophage cultures taken from septic mice had no further stimulatory effect. Sham controls alternatively showed no significant innate monokine release, but their macrophages did release increased monokine numbers in response to endotoxin. These results indicate that the spontaneous macrophage release of these monokines is comparable with that previously observed in endotoxin-sensitive mice, suggesting a common mechanism by which macrophages are primed by traumatic injury by an agent other than endotoxin to release monokines during sepsis. Thus, the administration of agents that decrease or prevent the deleterious effects of systemic inflammatory mediators during sepsis could be useful adjuvants in those clinical situations where the bacterial origin is unknown.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Right ventricular TNF resistance during endotoxemia: the differential effects on ventricular function
Markel et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;293:R1893-R1897.
ABSTRACT | FULL TEXT  

Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice
Wang et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;281:R1013-R1023.
ABSTRACT | FULL TEXT  

Lipopolysaccharide reduces intercellular coupling in vitro and arteriolar conducted response in vivo
Tyml et al.
Am. J. Physiol. Heart Circ. Physiol. 2001;281:H1397-H1406.
ABSTRACT | FULL TEXT  

Lipopolysaccharide Pretreatment Protects from Renal Ischemia/Reperfusion Injury : Possible Connection to an Interleukin-6-Dependent Pathway
Heemann et al.
Am. J. Pathol. 2000;156:287-293.
ABSTRACT | FULL TEXT  

Sepsis: Lessons Learned in the Last Century and Future Directions
Chaudry
Arch Surg 1999;134:922-929.
FULL TEXT  

Tumor necrosis factor in the heart
Meldrum
Am. J. Physiol. Regul. Integr. Comp. Physiol. 1998;274:R577-R595.
ABSTRACT | FULL TEXT  

Increased Mucosal B-Lymphocyte Apoptosis During Polymicrobial Sepsis Is a Fas Ligand But Not an Endotoxin-Mediated Process
Ayala et al.
Blood 1998;91:1362-1372.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.